Rituximab, bendamustine, and cytarabine followed by venetoclax in older patients with high-risk mantle cell lymphoma (FIL_V-RBAC): a multicentre, single-arm, phase 2 studyCarlo Visco, Monica Balzarotti, Maria Elena Carazzolo et al.|The Lancet Haematology|2025Cited by 6
<i>TP53</i>, <i>CD36</i> Mutations and <i>CDKN2A</i> Loss Predict Poor Outcome in Mantle Cell Lymphoma: Molecular Analysis of the FIL V-Rbac Phase 2 TrialRiccardo Moia, Carlo Visco, Maria Elena Carazzolo et al.|Blood|2024Cited by 3
<i>CAT</i> rs1001179 Single Nucleotide Polymorphism Identifies an Aggressive Clinical Behavior in Chronic Lymphocytic LeukemiaMarilisa Galasso, Maria Teresa Scupoli, Vittoria Salaorni et al.|Hematological Oncology|2024Cited by 1
Secondary Genetic Events and Their Relationship to TP53 Mutation in Mantle Cell Lymphoma: A Sub-Study from the FIL_MANTLE-FIRST BIO on Behalf of Fondazione Italiana Linfomi (FIL)Maria Elena Carazzolo, Carlo Visco, Francesca Maria Quaglia et al.|Cancers|2025Cited by 1
Author response for "<i>CAT</i> rs1001179 Single Nucleotide Polymorphism Identifies an Aggressive Clinical Behavior in Chronic Lymphocytic Leukemia"Marilisa Galasso, Maria Teresa Scupoli, Vittoria Salaorni et al.|Unknown|2024Cited by 0